Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury
Open Access
- 14 February 2018
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 6 (2), 1-8
- https://doi.org/10.14218/jcth.2017.00071
Abstract
Background and Aims: Acetaminophen (APAP) and HMG-CoA reductase inhibitors are common causes of drug-induced liver injury (DILI). This study aimed to determine the ability to reduce APAP- and statins-mediated liver injury by using formulations that combine glycosphingolipids and vitamin E.Keywords
This publication has 49 references indexed in Scilit:
- T-helper cell-mediated factors in drug-induced liver injuryJournal of Applied Toxicology, 2015
- Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver InjurySeminars in Liver Disease, 2014
- An Update on Drug-induced Liver InjuryJournal of Clinical and Experimental Hepatology, 2012
- Drug-induced liver injuryCurrent Opinion in Gastroenterology, 2012
- Role of immune reactions in drug-induced liver injury (DILI)Drug Metabolism Reviews, 2012
- Mechanisms of drug-induced liver injury: from bedside to benchNature Reviews Gastroenterology & Hepatology, 2011
- Acetaminophen HepatotoxicityClinics in Liver Disease, 2007
- Acetaminophen safety and hepatotoxicity – where do we go from here?Expert Opinion on Drug Safety, 2007
- Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registryJournal of Hepatology, 2006
- Acetaminophen hepatotoxicity: An updateCurrent Gastroenterology Reports, 1999